Lilly, Merus to develop T-cell redirecting bispecific antibodies

By The Science Advisory Board staff writers

January 19, 2021 -- Eli Lilly research and development group Loxo Oncology and oncology firm Merus have signed a research collaboration and exclusive license agreement with the goal of developing up to three CD3-engaging T-cell redirecting bispecific antibody therapies.

Under the deal, Merus will lead discovery and early-stage research efforts, while Loxo Oncology will handle additional research, development, and commercialization activities. Merus will receive $40 million in cash upfront, as well as an additional $20 million in equity investment by Lilly in Merus common shares, according to the vendors.

What's more, Merus is also eligible to receive up to $540 million in potential development and commercialization milestones per product, for a total of up to approximately $1.6 billion for three products. In addition, it will receive tiered royalties on product sales of any therapy commercialized from this collaboration, the companies said.


Copyright © 2021 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.